Clinical OMICS

MAR-APR 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/958440

Contents of this Issue

Navigation

Page 47 of 51

Precision Medicine 46 Clinical OMICs March/April 2018 www.clinicalomics.com the work of MCGI is researching both patient outcomes and whether doctors use the resources provided by the ini- tiative in their daily practice. "The other thing that is important is that [JAX] could bring everyone together," Harb noted. "Before this ini- tiative, there wasn't a lot of interaction between the different hospitals and cancer centers in the state. Through this initiative, we have been able share more ideas and to interact with each other in ways we wouldn't have without it." As Liu sees it, this is critical. "The natural tendency for [other organi- zations] would be to do a clinical study on the efficacy of the test itself. But with only 1,800 samples, there is no way to do that. The creativity we brought was understanding that is not the question. The question is: Is the community learning? Will we be more prepared three years from now than when we first started?" Patients also play a critical role in the work of MCGI. In exchange for receiv- ing the genomic testing at no cost, the patients are surveyed at enrollment and again later in their treatment. This helps the MCGI collect data on the patient experience, a critical component of val- ue-based reimbursement schemes. Currently, MCGI expects to remain active through the middle of 2021, though Rueter noted much of the last year will be devoted to collecting and analyzing data from both the patients and their doctors. "Our goal is to make this sustain- able over time," Antov said. "We want to use the initiative as a platform for additional research projects and as a precedent that would change current practices and the barriers that exist for ordering genomics tests." For Liu, he sees the program as a proof-of-concept of how to properly leverage remote technology to speed adoption of genomic medicine. JAX may be uniquely suited to this chal- lenge he noted, since its remote loca- tion in Bar Harbor, ME made it an early adopter of teleconferencing and other remote technologies. Baked into the organizational DNA of JAX is how to best leverage these technologies while also understanding their practi- cal limits. This is vital, if the model of deliver- ing care is to be changed. "The truth is, healthcare as currently constructed, is not scalable, and unless you take advantage of some of these IT capa- bilities, it will never be scalable," Liu noted. The Innovation Institute Taps 2bPrecise to Deliver POC Pharmacogenomics The Innovation Institute—a for-profit company comprising six member-owner health systems—announced it has cho- sen 2bPrecise to leverage its cloud-based, EHR-agnostic platform to deliver pharma- cogenomics information to the clinical point of care for the Institute's members, as well as other health systems outside the network. Under the terms of the agreement, 2bPrecise will leverage its precision medi- cine platform to allow clinicians to access the information from GeneFolio, a phar- macogenomics test and knowledge base developed by Avera Health—an Institute member—to help guide medication se- lection for individual patients based on their genetic profile. "Pharmacogenomics is poised for rap- id healthcare adoption to improve treat- ment success and Avera has been de- veloping and advancing the integration for almost a decade," said Krista Bohlen, director of personalized medicine at the Avera Institute for Human Genetics, in a prepared statement. Delivery of the results to clinicians via the 2bPrecise platform is not only within Avera's network in the Midwest, but also to the oth- er five members of The Innovation Institute comprising 125 hospitals in 20 states. Other members include Bon Secours Health Sys- tem, CHOC Children's, Franciscan Mission- aries of Our Lady, Mercy Health, and Provi- dence St. Joseph Health. n (continued from previous page) Once a month, MCGI convenes a genomic tumor board that includes that leverages expertise from major cancer centers and research hospital using teleconferencing. pe-art / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAR-APR 2018